title: Expression profile as predictor of relapse after adjuvant treatment in gastric cancer.
abstract: BACKGROUND
  TNM and histological subtype are the most important prognostic criteria in gastric cancer. In this study, we have tried to identify an immunohistochemical protein profile involved in gastric recurrence after a radical surgery.
  
  
  METHODS
  In this paper, protein panels involved in gastric carcinogenesis and progression was analyzed by immunohistochemistry expression: p53, Ki-67, Bcl-2, COX-2, c-erb-B2, EPO-R, E-cadherin, and β-catenin in 44 gastrectomy samples coming from gastrectomy pieces of patients diagnosed and operated on adenocarcinoma of the stomach followed by adjuvant treatment based on MacDonald chemoradiation regimen. An immunostaining profile that could predict the relapse after the end of adjuvant treatment was tried to find. These results have shown that the expression of the adverse prognostic protein profile based on positive p53 immunohistochemical expression and non-conserved E-cadherin/B-catenin staining is associated with tumor recurrence and a poor disease-free survival in operated gastric cancer patients with curative intent followed by adjuvant chemoradiation according to MacDonald's regimen. A protein profile based on immunohistochemical expression of p53 and E-cadherin-B-catenin that has a significant correlation to disease-free survival was identified in gastric cancer samples.
authors.affiliation: Medical Oncology Department, Infanta Sofía Hospital, San Sebastian de los Reyes, Madrid, Spain, ZC 28 701. mariasereno@yahoo.es
authors.forename: María
authors.initials: M
authors.lastname: Sereno
authors.forename: Javier
authors.initials: J
authors.lastname: De Castro
authors.forename: Paloma
authors.initials: P
authors.lastname: Cejas
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: García-Cabezas
authors.forename: Cristóbal
authors.initials: C
authors.lastname: Belda
authors.forename: Enrique
authors.initials: E
authors.lastname: Casado
authors.forename: Jaime
authors.initials: J
authors.lastname: Feliu
authors.forename: César
authors.initials: C
authors.lastname: Gómez
authors.forename: Miriam
authors.initials: M
authors.lastname: López
authors.forename: Manuel González
authors.initials: MG
authors.lastname: Barón
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D015820:Cadherins / Q000032:analysis / Q000096:biosynthesis; D059186:Chemoradiotherapy, Adjuvant; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000378:metabolism* / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000096:biosynthesis; D051176:beta Catenin / Q000032:analysis / Q000096:biosynthesis
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D051176:beta Catenin